ReviewMolecular diagnosis & therapy2021
Piflufolastat F 18: Diagnostic First Approval.
Review in Molecular diagnosis & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07635524 (A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Novel PSCA-Targeting Adapter Molecules for Late-Stage RevCAR-T Cell Therapy in Prostate Cancer.International journal of molecular sciences · 2026Article
- FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland) · 2026Review
- Exclusively ChemoselectiveACS omega · 2026Article
- Leveraging [Clinical and translational science · 2026Article
- Second generation PSMA-targeted turn-on probe for imaging cargo release in prostate cancer cells.Bioorganic & medicinal chemistry letters · 2026Article
- [ACS omega · 2026Article
- CAR-T Cell Therapy for Prostate Cancer: Current Advances and Future Perspectives.Biomedicines · 2025Review
- RNA Nanoparticles Harboring Radioisotopes or Other Imaging Molecules for Spontaneous Tumor Targeting for Early Cancer Diagnosis.RNA nanomed · 2025Article
- Rapid cleavage of 6-[EJNMMI radiopharmacy and chemistry · 2025Article
- Review
- Cobalt(III) Halide Metal-Organic Frameworks Drive Catalytic Halogen Exchange.Journal of the American Chemical Society · 2024Article
- Radiosynthesis, structural identification and in vitro tissue binding study of [EJNMMI radiopharmacy and chemistry · 2024Article
- FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect.Heliyon · 2024Review
- Highlights on U.S. FDA-approved fluorinated drugs over the past five years (2018-2022).European journal of medicinal chemistry · 2023Review
- Designed ankyrin repeat proteins for detecting prostate-specific antigen expressionRSC chemical biology · 2023Article
- FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022.International journal of molecular sciences · 2023Review
- Phase I Trial of [Cancers · 2023Article
- Predicting Outcomes of Indeterminate Bone Lesions onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Copper-Mediated Radiobromination of (Hetero)Aryl Boronic Pinacol Esters.The Journal of organic chemistry · 2023Article
- A rapid and systematic approach for the optimization of radio thin-layer chromatography resolution.Journal of chromatography. A · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Piflufolastat F 18 (PYLARIFY
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.